证券代码：002262 证券简称：恩华药业 公告编号：2025-058 江苏恩华药业股份有限公司 关于召开 2025 年第二次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或 重大遗漏。 江苏恩华药业股份有限公司（ 以下简称：公司）第七届董事会第五次会议于 2025 年 12 月 3 日在 徐州市经济技术开发区龙湖西路 31 号恩华科技大厦 20 楼会议室召开，会议决定于 2025 年 12 月 19 日 （星期五）召开 2025 年第二次临时股东大会。本次股东大会采用现场投票及网络投票相结合的方式进 行，现将有关事项通知如下： 一、召开会议的基本情况 1、股东大会届次：2025 年第二次临时股东大会。 2、股东大会的召集人：董事会。 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所股票上市规则》《深圳 证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等法律、行政法规、部门规章、 规范性文件及《公司章程》的有关规定。 4、本次股东大会的召开时间： （1）现场会议时间：2025 年 12 月 19 日（星期五）上午 9 ...

（1）根据《公司法》《关于新<公司法>配套制度规则实施相关过渡期安排》和《上 市公司章程指引（2025年修订）》以及《深圳证券交易所股票上市规则》等相关法律、 法规、规范性文件的规定，公司拟取消监事会、不设监事，由董事会审计委员会行使 《公司法》和监管制度规定的监事会职权，同时《监事会议事规则》相应废止，公司各 项规章制度中涉及公司监事会、监事的规定不再适用。在公司股东大会审议通过取消监 事会事项之前，公司第七届监事会仍将严格按照《公司法》等有关法律法规和《公司章 程》的规定继续履行监督职能，维护公司和全体股东利益。 证券代码：002262 证券简称：恩华药业 公告编号：2025-056 江苏恩华药业股份有限公司 第七届监事会第五次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 一、监事会会议召开情况 江苏恩华药业股份有限公司（以下简称：公司）监事会于2025年11月21日以电子邮 件及专人送达的方式向全体监事发出召开第七届监事会第五次会议的通知及相关会议资 料。2025年12月3日下午1：00至3：00，第七届监事会第五次会议在徐州市经济技术开发 ...

证券代码：002262 证券简称：恩华药业 公告编号：2025-055 江苏恩华药业股份有限公司 第七届董事会第五次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确、完整，对公告的虚假记载、误导性 陈述或重大遗漏负连带责任。 一、董事会会议召开情况 江苏恩华药业股份有限公司（以下简称：公司）第七届董事会第五次会议于 2025 年 12 月 3 日在徐州市经济技术开发区龙湖西路 31 号恩华科技大厦 20 楼会议室召开，会议通知已 于 2025 年 11 月 21 日以专人送达、传真、电子邮件等方式送达给全体董事、监事和高级管理 人员。本次会议应到董事 8 名，实到董事 8 名。公司监事和高级管理人员亦列席本次会议。 本次会议由董事长孙彭生先生召集并主持。本次会议的召集、召开程序符合有关法律法规和 公司章程的规定。 二、董事会会议审议情况 经与会董事书面表决，会议形成如下决议： 1、会议以8票赞成、0票反对、0票弃权的表决结果审议通过了《关于取消监事会、变更 经营范围、增加董事会人数、修订<公司章程>并办理工商变更登记的议案》。 （1）根据《公司法》《关于新<公司法>配套制度规则实施相关过渡期安排》和 ...

Core Insights - The article highlights the positive performance of the pharmaceutical sector in the stock market, with specific stocks like Huatai Medical and Te Bao Bio showing significant gains [1] - The State Council meeting on November 27, 2025, emphasized the importance of provincial-level coordination in basic medical insurance as a key measure to improve the national healthcare system [1][2] - The upgrade of medical insurance coordination is expected to enhance the risk resistance of funds, improve fairness in the system, and facilitate easier access for insured individuals [2] Industry Summary - The medical insurance provincial coordination aims to balance fund income and expenditure across regions, addressing the disparity between economically developed and underdeveloped areas [2] - The initiative is expected to create structural opportunities in the pharmaceutical industry, particularly benefiting sectors such as innovative drugs, medical information technology, and medical devices [2] - The Medical Innovation ETF has seen a net inflow of 12.13 million yuan recently, indicating strong investor interest in the pharmaceutical sector [2] Company Summary - The Medical Innovation ETF (516820) includes 30 leading pharmaceutical stocks, with a focus on innovative drugs (34%), CXO (17%), medical devices (13%), and consumer healthcare (11%) [2] - The current market shows significant differentiation within the pharmaceutical sector, with high valuations in innovative drugs, while CXO, medical devices, and consumer healthcare sectors have potential for upward movement [2]

公司要闻： 国邦医药（605507）：公司发布公告，公司拟对董事、高管在内的270名员工实施员工持股计划，拟筹 集资金总额不超过1.85 亿元，涉及的股票总数不超过股本总额的10%，存续期为24 个月，锁定期为12 个月。 泰恩康（301263）：公司发布公告，子公司山东华铂凯盛于近日收到国家药品监督管理局签发的巴瑞替 尼片《药品注册证书》，经审查，本品符合药品注册的有关要求，批准注册。 一品红（300723）：公司发布公告，子公司广州一品红于近日收到国家药品监督管理局核准签发的艾司 奥美拉唑镁肠溶干混悬剂《药品注册证书》，，经审查，本品符合药品注册的有关要求，批准注册。 恩华药业（002262）：公司发布公告，近日收到国家药品监督管理局签发的盐酸羟考酮缓释片《药品注 册证书》，经审查，本品符合药品注册的有关要求，批准注册。 市场表现： 2025 年11 月28 日，医药板块涨跌幅+0.14%，跑输沪深300 指数0.11pct，涨跌幅居申万31 个子行业第27 名。各医药子行业中，医疗设备(+1.53%)、医院（+0.95%)、其他生物制品(+0.70%)表现居前，线下药 店（-0.55%）、疫苗(-0.4 ...

Core Viewpoint - The report highlights the trends and statistics in the Chinese chemical pharmaceutical industry, indicating a slight decline in production while maintaining overall growth in the first nine months of 2025 [1]. Industry Summary - In September 2025, the production of chemical pharmaceutical raw materials in China was 295,000 tons, representing a year-on-year decrease of 3.6% [1]. - Cumulatively, from January to September 2025, the total production of chemical pharmaceutical raw materials reached 2.721 million tons, showing a cumulative growth of 1.2% [1]. - The report is based on data from the National Bureau of Statistics and is compiled by Zhiyan Consulting, a leading industry consulting firm in China [1]. Company Summary - Listed companies in the chemical pharmaceutical sector include Heng Rui Medicine (600276), East China Pharmaceutical (000963), Lizhu Group (000513), Baiyunshan (600332), North China Pharmaceutical (600812), Haizheng Pharmaceutical (600267), Fosun Pharmaceutical (600196), Kelun Pharmaceutical (002422), Enhua Pharmaceutical (002262), and Xianju Pharmaceutical (002332) [1].

本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性陈 述或重大遗漏。 公司于近日获得国家药品监督管理局核准签发的化学药品盐酸羟考酮缓释片的《药品注册 证书》，现将相关情况公告如下： 1、盐酸羟考酮缓释片《药品注册证书》的详细情况见下表： | 药品通用名称 | | 盐酸羟考酮缓释片 | | --- | --- | --- | | 受理号 | | CYHS2401532 | | 证书编号 | | 2025S03554 | | 规 | 格 | 40mg | | 剂 | 型 | 片剂 | | 申请事项 | | 药品注册（境内生产） | | 注册分类 | | 化学药品 4 类 | | 药品有效期 | | 18 个月 | | 审批结论 | | 根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品 注册的有关要求，批准注册，发给药品注册证书。 | | 药品批准文号 | | 国药准字 H20256076 | | 药品批准文号有效 | 期 | 至 2030 年 11 月 24 日 | 证券代码：002262 证券简称：恩华药业 公告编号：2025-054 江苏恩华药业股份有限公司 关于获得《 ...

格隆汇11月28日丨恩华药业(002262.SZ)公布，公司于近日获得国家药品监督管理局核准签发的化学药 品盐酸羟考酮缓释片的《药品注册证书》，盐酸羟考酮缓释片是本公司自主研发，采用物理化学屏障技 术实现口服阿片类药物防滥用效果的缓释制剂，用于治疗严重到需要长期持续、每天按时使用阿片类药 物治疗、且替代治疗（例如：非阿片类药物或速释阿片类药物）不能充分缓解的疼痛，在确保疗效的前 提下，有效提升了用药安全性。 ...

Group 1: Core Insights - The current wave of innovative drugs is driven by China's participation in new technologies, with advancements in ADC, bispecific antibodies, second-generation IO, and GLP-1 [1] - The global pharmaceutical transaction volume has steadily increased, with total transaction amounts rising from $56.9 billion to $187.4 billion over the past decade, while China's transaction amounts surged from $3.1 billion to $57.1 billion [1] - By 2024, China's transaction volume is expected to account for approximately 30% of global pharmaceutical transactions [1] Group 2: Sector Analysis - In oncology, the combination of IO and ADC therapies remains strong, with significant transactions in the PD-1 bispecific antibody space; the sales of Pembrolizumab are projected to reach $29.482 billion in 2024 [2] - The autoimmune disease sector is witnessing a shift as older drugs face patent expirations, with new opportunities emerging in Th2 and Th17 pathways; Dupilumab is expected to lead with $14.1 billion in sales in 2024 [2] - The cardiovascular and metabolic disease market continues to grow, with GLP-1 receptor agonists projected to exceed $50 billion in global sales in 2024 [3] Group 3: Future Technologies - New technologies such as next-generation ADCs, TCE therapies, universal/in vivo CART technologies, gene therapy, and small nucleic acid technologies are anticipated to lead future disease treatments [4]

Investment Rating - The report maintains an "Outperform" rating for several companies including Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical [6][7]. Core Insights - The report continues to recommend innovative pharmaceuticals and the industry chain, highlighting the high prosperity in innovative drugs and the potential for value re-evaluation [6][26]. - The A-share pharmaceutical sector underperformed the market in the third week of November 2025, with the SW Pharmaceutical and Biological index falling by 6.9% compared to a 3.9% drop in the SHCOMP [9][19]. - The report identifies top gainers and losers in the A-share market, with Hainan Haiyao (+23.8%) and Remed (+13.9%) being the top gainers, while GDK (-25.5%) and Nanjing Hicin Pharmaceutical (-23.2%) were the biggest losers [16][19]. - The premium level of the pharmaceutical sector relative to all A-shares is currently at a normal level, with a relative premium rate of 71.8% as of November 21, 2025 [18][22]. Summary by Sections 1. Continued Recommendation for Innovative Pharmaceuticals and Industry Chain - The report emphasizes the ongoing recommendation for innovative drugs and the industry chain, maintaining "Outperform" ratings for various companies in the pharmaceutical and biotech sectors [6][26]. 2. A-share Pharmaceutical Sector Performance - In the third week of November 2025, the A-share pharmaceutical sector underperformed the broader market, ranking 23rd among Shenwan primary industries [9][19]. 3. Hong Kong and U.S. Market Performance - The Hong Kong pharmaceutical sector also underperformed, with the Hang Seng Healthcare index falling by 7.5%, while the U.S. pharmaceutical sector outperformed, with the S&P Healthcare Select Sector rising by 1.8% [19][26].